BRAF and glioma: Dual inhibition of the MAPK pathway using the BRAF and MEK inhibitors dabrafenib and trametinib, respectively, resulted in durable clinical benefit for patients with BRAF V600E mutant low-grade and high-grade glioma according to results from a phase II ROAR study (NCT02034110) virtually presented by Vivek Subbiah, MD, at the AACR Annual Meeting in 2021.